

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	1
SCOPE OF REPORT.....	1
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ABOUT THE AUTHOR.....	2
RELATED BCC RESEARCH REPORTS.....	2
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	3
 CHAPTER TWO: SUMMARY.....	 4
<i>SUMMARY TABLE GLOBAL DERMATOLOGICAL THERAPEUTICS</i> <i>REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013</i> <i>(\$ BILLIONS).....</i>	 5
<i>SUMMARY FIGURE GLOBAL DERMATOLOGICAL THERAPEUTICS</i> <i>REVENUE FORECAST BY MARKET SEGMENT, 2008 AND 2013 (%).....</i>	 6
 CHAPTER THREE: OVERVIEW.....	 7
HUMAN SKIN.....	7
<i>TABLE 1 FUNCTIONS OF THE SKIN.....</i>	<i>7</i>
<i>TABLE 1 (CONTINUED).....</i>	<i>8</i>
SKIN DISORDERS.....	9
<i>TABLE 2 DISORDERS OF THE SKIN.....</i>	<i>9</i>
<i>TABLE 2 (CONTINUED).....</i>	<i>10</i>
<i>TABLE 2 (CONTINUED).....</i>	<i>11</i>
<i>TABLE 2 (CONTINUED).....</i>	<i>12</i>
ACNE.....	13
<i>TABLE 3 TYPES OF ACNE.....</i>	<i>13</i>
ROSACEA.....	13
<i>TABLE 4 TYPES OF ROSACEA.....</i>	<i>14</i>
<i>TABLE 5 DRUGS AND THEIR ACTION AGAINST ACNE AND ROSACEA... ..</i>	<i>14</i>
BACTERIAL INFECTIONS OF THE SKIN.....	15
<i>TABLE 6 TYPES OF BACTERIAL INFECTIONS OF THE SKIN.....</i>	<i>15</i>
<i>TABLE 6 (CONTINUED).....</i>	<i>16</i>
<i>TABLE 6 (CONTINUED).....</i>	<i>17</i>
<i>TABLE 7 SOME PRESCRIPTION DRUGS PRESCRIBED TO TREAT</i> <i>BACTERIAL SKIN INFECTIONS.....</i>	 17
<i>TABLE 7 (CONTINUED).....</i>	<i>18</i>
<i>TABLE 7 (CONTINUED).....</i>	<i>19</i>
BENIGN SKIN GROWTHS OR TUMORS.....	19
<i>TABLE 8 TYPES OF BENIGN SKIN GROWTHS OR TUMORS.....</i>	<i>19</i>
<i>TABLE 8 (CONTINUED).....</i>	<i>20</i>

<i>TABLE 9 SOME PRESCRIPTION DRUGS USED TO TREAT BENIGN SKIN GROWTHS</i>	20
<i>TABLE 9 (CONTINUED)</i>	21
<i>BULLOUS DISORDERS OR BLISTERING DISEASES</i>	21
<i>TABLE 10 TYPES OF BULLOUS DISORDERS</i>	21
<i>TABLE 10 (CONTINUED)</i>	22
<i>TABLE 11 SOME PRESCRIPTION DRUGS USED TO TREAT BULLOUS SKIN DISORDERS</i>	22
<i>TABLE 11 (CONTINUED)</i>	23
<i>SKIN CANCERS</i>	23
<i>TABLE 12 TYPES OF SKIN CANCERS</i>	23
<i>TABLE 12 (CONTINUED)</i>	24
Types of Melanoma	24
Lentigo Maligna Melanoma.....	24
Superficial Spreading Melanoma	25
Nodular Melanoma	25
Acral-Lentiginous Melanoma	25
<i>TABLE 13 SKIN CANCER INCIDENCE IN THE U.S.</i>	26
<i>TABLE 14 SOME PRESCRIPTION DRUGS USED TO TREAT CUTANEOUS CARCINOMAS</i>	26
<i>CORNIFICATION DISORDERS</i>	27
Calluses and Corns	27
<i>TABLE 15 TYPES OF CALLUSES AND CORNS</i>	27
Ichthyosis or Dry Skin.....	27
<i>TABLE 16 TYPES OF ICHTHYOSIS</i>	27
<i>TABLE 16 (CONTINUED)</i>	28
Keratosis Pilaris	28
<i>TABLE 17 TYPES OF KERATOSIS PILARIS</i>	28
Sebaceous Cysts.....	29
Dermatitis	29
<i>TABLE 18 TYPES OF DERMATITIS</i>	29
<i>TABLE 18 (CONTINUED)</i>	30
<i>TABLE 19 SOME DRUGS PRESCRIBED FOR DERMATITIS</i>	31
Fungal Infections of the Skin.....	31
<i>TABLE 20 TYPES OF FUNGAL INFECTIONS OF THE SKIN</i>	32
<i>TABLE 20 (CONTINUED)</i>	33
<i>TABLE 21 SOME DRUGS PRESCRIBED TO TREAT FUNGAL INFECTIONS OF THE SKIN</i>	33
<i>TABLE 21 (CONTINUED)</i>	34
<i>HYPERSENSITIVITY AND INFLAMMATORY DISORDERS</i>	34
Acute Febrile Neutrophilic Dermatosi (Sweet's Syndrome)	34
Drug Eruptions and Reactions.....	34
<i>TABLE 22 TYPES OF DRUG REACTIONS AND TYPICAL CAUSATIVE AGENTS</i>	35

<i>TABLE 22 (CONTINUED)</i>	36
Erythema Multiforme.....	36
<i>TABLE 23 TYPES OF ERYTHEMA MULTIFORME</i>	37
Erythema Nodosum.....	37
Granuloma Annulare.....	37
Panniculitis.....	37
Pyoderma Gangrenosum	37
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis...	38
Bed Sore	38
Pityriasis Rosea	38
<i>TABLE 24 SOME DRUGS PRESCRIBED TO TREAT HYPERSENSITIVITY AND INFLAMMATORY DISORDERS</i>	38
<i>TABLE 24 (CONTINUED)</i>	39
PARASITIC INFECTIONS OF THE SKIN	39
<i>TABLE 25 TYPES OF PARASITIC INFECTION OF THE SKIN</i>	39
<i>TABLE 25 (CONTINUED)</i>	40
<i>TABLE 26 SOME DRUGS PRESCRIBED TO TREAT PARASITIC INFECTIONS OF THE SKIN</i>	41
PSORIASIS AND SCALING DISEASES.....	41
<i>TABLE 27 TYPES OF PSORIASIS AND SCALING DISEASES</i>	42
Psoriasis Treatment	43
PIGMENTATION DISORDERS.....	43
<i>TABLE 28 TYPES OF PIGMENTATION DISORDERS</i>	44
Birthmarks.....	44
Poison Ivy.....	44
<i>TABLE 29 SOME PRESCRIPTION DRUGS FOR PIGMENTATION DISORDERS</i>	45
REACTIONS TO SUNLIGHT	45
Aging	45
Actinic Keratoses	46
Skin Cancers.....	46
Photosensitivity	46
<i>TABLE 30 TYPES OF PHOTSENSITIVITY</i>	46
Sunburn	47
SWEATING DISORDERS	47
<i>TABLE 31 TYPES OF SWEATING DISORDERS</i>	47
VIRAL SKIN DISEASES	48
<i>TABLE 32 TYPES OF VIRAL SKIN DISEASES</i>	48
<i>TABLE 32 (CONTINUED)</i>	49
<i>TABLE 33 SOME DRUGS PRESCRIBED TO TREAT VIRAL DISEASES OF THE SKIN</i>	49
<i>TABLE 33 (CONTINUED)</i>	50
COMMON DIAGNOSTIC TESTS FOR SKIN DISORDERS.....	50
DERMOSCOPY	50

PATCH TESTING	50
SKIN BIOPSY	51
CULTURE	51
PHOTOTESTS.....	51
MORBIDITY/PREVALENCE.....	52
<i>TABLE 34 SKIN DISORDER MORBIDITY IN THE U.S. BY AGE AND</i>	
<i>CAUSE (THOUSANDS).....</i>	<i>53</i>
THERAPEUTIC PROCEDURES FOR THE SKIN	53
CANCER SURGERY.....	53
Excisional Biopsy to Remove Skin Cancer	53
Curettage and Electrocautery	54
Mohs Micrographic Surgery (MMS).....	54
Wide Local Excision.....	54
Skin Grafting	54
Lymph Node Removal	55
CHEMICAL PEELS	56
CRYOTHERAPY/CRYOSURGERY.....	57
Ice Packs	57
Cold Gel Packs	58
Ice Immersion	58
Ice Massage.....	58
Vapocoolant Sprays	58
RADIOTHERAPY	58
CHEMOTHERAPY	59
Chemotherapy Creams.....	59
Chemotherapy into a Vein	59
LASER SURGERY	60
<i>TABLE 35 SKIN CONDITIONS REQUIRING ONLY LASER SURGERY.....</i>	<i>60</i>
<i>TABLE 35 (CONTINUED).....</i>	<i>61</i>
<i>TABLE 35 (CONTINUED).....</i>	<i>62</i>
Carbon Dioxide Laser.....	62
YAG Laser.....	63
Pulsed Dye Laser or Argon Laser	63
Excimer Laser.....	63
<i>TABLE 36 ADVANTAGES AND DISADVANTAGES OF EXCIMER LASER ...</i>	<i>64</i>
PHOTODYNAMIC THERAPY	64
<i>TABLE 37 VARIOUS CANCERS TREATABLE BY PDT.....</i>	<i>65</i>
Application in Dermatology	66
<i>TABLE 38 VARIOUS SKIN DISORDERS TREATABLE BY PDT.....</i>	<i>67</i>
Goeckerman Treatment.....	67
PUVA	67
Ultraviolet B Phototherapy	68
Broadband	68
Narrowband	68

<i>TABLE 39 ADVANTAGES AND DISADVANTAGES OF UVB THERAPY</i>	69
SCLEROTHERAPY.....	69
CHAPTER FOUR: PRESCRIPTION DERMATOLOGICAL DRUGS.....	70
SYSTEMIC DRUGS.....	70
ACITRETIN.....	71
CLINDAMYCIN.....	72
ERYTHROMYCIN.....	72
CYCLOSPORINE.....	73
<i>TABLE 40 ADVANTAGES AND DISADVANTAGES OF CYCLOSPORINE</i>	74
METHOTREXATE.....	74
<i>TABLE 41 ADVANTAGES AND DISADVANTAGES OF METHOTREXATE</i> ...	75
THALIDOMIDE.....	75
SYSTEMIC ANTIBACTERIAL AGENTS.....	76
Antileprotic Drugs (Including Dapsone).....	76
Antimalarial Drugs (Including Hydroxychloroquine).....	77
SYSTEMIC ANTIFUNGAL AGENTS.....	78
SYSTEMIC ANTIHISTAMINES.....	78
SYSTEMIC ANTIPARASITIC AGENTS.....	79
SYSTEMIC ANTIPRURITIC AGENTS.....	79
SYSTEMIC ANTIVIRAL AGENTS.....	79
SYSTEMIC CORTICOSTEROIDS.....	80
SYSTEMIC INTERFERONS.....	80
SYSTEMIC RETINOID.....	81
OTHER SYSTEMIC DRUGS.....	82
6-Thioguanine.....	82
Hydroxyurea.....	82
Mycophenolate Mofetil.....	82
Sulfasalazine.....	83
BIOLOGICAL THERAPIES (BIOLOGICS).....	83
Colchicine.....	84
CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS.....	85
Retinoids.....	86
Hormones and Anti-Androgens.....	86
Hormones and ... (Continued).....	87
TOPICAL TREATMENTS.....	88
ACICLOVIR.....	88
TOPICAL RETINOIDS.....	88
ANTHRALIN.....	89
<i>TABLE 42 ADVANTAGES AND DISADVANTAGES OF ANTHRALIN</i>	89
COAL TAR.....	89
<i>TABLE 43 ADVANTAGES AND DISADVANTAGES OF COAL TAR</i>	90
CORTICOSTEROIDS.....	90
<i>TABLE 44 ADVANTAGES AND DISADVANTAGES OF CORTICOSTEROIDS</i> 91	
<i>TABLE 45 TOPICAL CORTICOSTEROIDS, 2004</i>	91

<i>TABLE 45 (CONTINUED)</i>	92
<i>TABLE 45 (CONTINUED)</i>	93
RETINOID: TAZAROTENE	94
<i>TABLE 46 ADVANTAGES AND DISADVANTAGES OF TAZAROTENE</i>	94
VITAMIN D3: CALCIPOTRIENE	94
<i>TABLE 47 ADVANTAGES AND DISADVANTAGES OF CALCIPOTRIOL</i>	95
CAPSAICIN	96
TOPICAL MEDICATIONS IN CLINICAL TRIALS	96
MOISTURIZERS AND SCALE REMOVERS	97
<i>TABLE 48 DRUG TREATMENTS FOR SKIN DISEASE INTRODUCED IN</i> <i>2006</i>	97
<i>TABLE 48 (CONTINUED)</i>	98
<i>TABLE 48 (CONTINUED)</i>	99
<i>TABLE 48 (CONTINUED)</i>	100
<i>TABLE 48 (CONTINUED)</i>	101
<i>TABLE 48 (CONTINUED)</i>	102
CHAPTER FIVE: TECHNOLOGY REVIEW	103
EMERGING TECHNOLOGIES IN DERMATOLOGY	103
DNA MICROARRAY TECHNOLOGY IN DERMATOLOGY	103
ADVANCES IN THE TREATMENT OF VARICOSE VEINS.....	103
EMERGING TREATMENT OF ATOPIC DERMATITIS.....	103
EMERGING DRUGS FOR ICHTHYOSIS	104
PROGRESS IN THE MANAGEMENT OF ACNE	104
PLASMA SKIN REGENERATION TECHNOLOGY	104
<i>TABLE 49 NEW TECHNOLOGIES IN DERMATOLOGY</i>	105
<i>TABLE 49 (CONTINUED)</i>	106
PERMEATION ENHANCEMENT TECHNOLOGIES	106
Drug Permeation Enhancement via Buccal Route.....	107
Thiomatrix: Permeation Enhancement	108
Merrion's Technology: Gastrointestinal Permeation Enhancement Technology (GIPET).....	108
<i>FIGURE 1 GASTROINTESTINAL PERMEATION ENHANCEMENT</i> <i>TECHNOLOGY</i>	108
Transdermal Protein Delivery or Measurement Using Low- Frequency Sonophoresis	109
RADIOTHERAPY	110
External Radiotherapy	111
Conformal Radiotherapy	111
Intensity Modulated Radiotherapy.....	111
Internal Radiotherapy	112
Radioactive Implants.....	112
Radioactive Liquids	112
Radioactive ... (Continued).....	113
PLASMA SKIN REGENERATION	114

Plasma Skin ... (Continued).....	115
Plasma Skin ... (Continued).....	116
CHAPTER SIX: PATENT ANALYSIS.....	117
PATENT ISSUE TRENDS IN UNITED STATES	117
<i>FIGURE 2 U.S. PATENT TRENDS, 1990–2001</i>	117
<i>TABLE 50 NUMBER OF U.S. PATENTS ISSUED, 2003 TO JULY 31, 2008.</i>	118
<i>TABLE 51 COMPANIES AND NUMBER OF U.S. PATENTS FILED BY</i>	
<i>THEM, 2003 TO JULY 31, 2008</i>	118
<i>TABLE 52 RECENT DERMATOLOGY U.S. PATENTS</i>	119
<i>TABLE 52 (CONTINUED)</i>	120
<i>TABLE 52 (CONTINUED)</i>	121
<i>TABLE 52 (CONTINUED)</i>	122
PATENT ISSUE TRENDS IN EUROPE	122
<i>TABLE 53 EUROPEAN DERMATOLOGICAL PATENTS, 2003–JULY 2008.</i>	122
<i>TABLE 54 RECENT PATENTS ISSUED BY THE EPO</i>	123
<i>TABLE 54 (CONTINUED)</i>	124
CHAPTER SEVEN: INDUSTRY PARTICIPANT PROFILES	125
MANUFACTURERS OF DERMATOLOGICAL DRUGS	125
AGI DERMATICS	125
ALLERGAN, INC.	125
AMGEN, INC.....	126
ANACOR PHARMACEUTICALS.....	126
ANIKA THERAPEUTICS, INC.	127
ASTELLAS US, LLC.....	128
CHESTER VALLEY PHARMACEUTICALS, INC.....	129
CORIA LABORATORIES, LTD.....	129
CORIA LABORATORIES, LTD.....	129
DERMIK LABORATORIES, INC.....	129
DUSA PHARMACEUTICALS, INC.	130
EISAI, INC.	130
FERNDALE LABORATORIES, INC.	131
GALDERMA LABORATORIES.....	131
GENENTECH, INC.	131
ISOLAGEN, INC.	132
LEO PHARMA A/S.....	132
MEDICIS PHARMACEUTICAL CORP.....	133
MEDIMETRIKS PHARMACEUTICALS, INC.	134
MERZ PHARMA UK, LTD.	134
NEOSIL, INC.	135
NYCOMED U.S., INC.	135
OBAGI MEDICAL PRODUCTS, INC.	136
ONSET THERAPEUTICS	137
ORTHONEUTROGENA	137

PIERRE FABRE PHARMACEUTICALS, INC.....	138
PRIME PHARMACEUTICALS CORP.....	138
QLT, INC.	138
QUINNOVA PHARMACEUTICALS.....	139
SCHERING-PLOUGH CORP.....	139
SINCLAIR PHARMACEUTICALS	139
SKINMEDICA, INC.	140
STIEFEL LABORATORIES, INC.	141
SUMMERS LABORATORIES, INC.....	141
SYNTOPIX GROUP, PLC.....	141
TRIAx PHARMACEUTICALS, LLC.....	142
VALEANT PHARMACEUTICALS INTERNATIONAL.....	142
VALEO PHARMA, INC.	143
WARNER CHILCOTT, LTD.....	144
XOMA, LTD.....	144
NON-COMMERCIAL ORGANIZATIONS.....	145
AFRICAN ASSOCIATION OF DERMATOLOGY	145
AMERICAN ACADEMY OF DERMATOLOGY (AAD)	145
AMERICAN BEHCET'S DISEASE ASSOC., INC.....	145
AMERICAN CELIAC SOCIETY	145
AMERICAN HEMOCHROMATOSIS SOCIETY, INC.....	145
AMERICAN LUPUS SOCIETY.....	146
AMERICAN SKIN ASSOCIATION, INC.....	146
AMERICAN SOCIAL HEALTH ASSOC.....	146
ARTHRITIS FOUNDATION	146
ASIAN DERMATOLOGICAL ASSOCIATION	146
ASSOCIATION OF PROFESSORS OF DERMATOLOGY	147
ATAXIA-TELANGIECTASIA CHILDREN'S PROJECT	147
BASAL CELL CARCINOMA NEVUS SYNDROME/GORLIN SYNDROME.....	147
BAY AREA LUPUS FOUNDATION	147
BLOOM'S SYNDROME REGISTRY	147
BRITISH ASSOCIATION OF DERMATOLOGISTS.....	148
CELIAC DISEASE FOUNDATION	148
CELIAC SPRUE ASSOCIATION/USA	148
CICATRICIAL ALOPECIA RESEARCH FOUNDATION	148
COALITION OF SKIN DISEASES	148
CORNELIA DE LANGE SYNDROME FOUNDATION, INC.....	149
CUTANEOUS LYMPHOMA FOUNDATION.....	149
DERMATOLOGY FOUNDATION	149
DERMATOLOGY NURSES ASSOCIATION (DNA)	149
DERMATOPATHOLOGY FOUNDATION	149
DYSAUTONOMIA FOUNDATION, INC.....	149
DYSTROPHIC EPIDERMOLYSIS BULLOSA.....	150

THE ECTODERMAL DYSPLASIA SOCIETY	150
EHLERS DANLOS NATIONAL FOUNDATION (EDNF).....	150
EHLERS-DANLOS SYNDROME FOUNDATION.....	150
EUROPEAN ACADEMY FOR DERMATOLOGY AND VENEREOLGY	150
EADV Administrative Office.....	151
THE EUROPEAN DERMATOLOGY FORUM.....	151
EUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH ...	151
EUROPEAN UNION OF MEDICAL SPECIALISTS	151
FOUNDATION FOR ICHTHYOSIS AND RELATED SKIN TYPES (F.I.R.S.T.).....	152
GLUTEN INTOLERANCE GROUP (DERMATITIS HERPETIFORMIS)	152
HEMOCHROMATOSIS RESEARCH FOUNDATION	152
HIDRADENITIS SUPPURATIVA FOUNDATION, INC.....	152
HISTIOCYTOSIS ASSOCIATION OF AMERICA	153
INFLAMMATORY SKIN DISEASE INSTITUTE (ISDI).....	153
INTERNATIONAL FOUNDATION FOR DERMATOLOGY.....	153
THE INTERNATIONAL LEAGUE OF DERMATOLOGICAL SOCIETIES OFFICE.....	153
INTERNATIONAL PEMPHIGUS PEMPHIGOID FOUNDATION..	153
THE INTERNATIONAL SOCIETY OF DERMATOPATHOLOGY..	154
KLIPPEL-TRENAUNAY SUPPORT GROUP	154
LUPUS FOUNDATION OF AMERICA, INC.	154
LYMPHOMA RESEARCH FOUNDATION.....	154
LYMPHOMATOID PAPULOSIS CENTRAL REGISTRY	154
MARFAN ASSOC. U.K.	155
THE MELANOMA RESEARCH FOUNDATION.....	155
MUSCULAR DYSTROPHY ASSOC.....	155
MYOSITIS ASSOCIATION OF AMERICA (MAA)	155
NATIONAL ALOPECIA AREATA FOUNDATION (NAAF)	155
NATIONAL ATAXIA FOUNDATION.....	156
NATIONAL ECZEMA ASSOCIATION (NEA)	156
NATIONAL ECZEMA ASSOCIATION FOR SCIENCE AND EDUCATION	156
NATIONAL ECZEMA SOCIETY	156
NATIONAL EPIDERMOLYSIS BULLOSA REGISTRY	156
NATIONAL FOUNDATION FOR ECTODERMAL DYSPLASIAS ...	157
NATIONAL FOUNDATION FOR VITILIGO AND PIGMENT DISORDERS	157
NATIONAL INCONITENTIA PIGMENTI FOUNDATION	157
NATIONAL MEDICAL ASSOC.....	157
NATIONAL NEUROFIBROMATOSIS FOUNDATION	157

NATIONAL ORGANIZATION FOR ALBINISM AND HYPOPIGMENTATION (NOAH)	158
NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) ..	158
THE NATIONAL PEMPHIGUS FOUNDATION	158
NATIONAL PSORIASIS FOUNDATION	158
NATIONAL REGISTRY FOR ICHTHYOSIS AND RELATED DISORDERS	158
NATIONAL VITILIGO FOUNDATION.....	159
NEVOID BASAL CELL CARCINOMA SYNDROME SUPPORT NETWORK.....	159
PACHYONYCHIA CONGENITA PROJECT.....	159
THE PSORIASIS ASSOC.	159
SCLERODERMA FEDERATION, INC.....	159
SCLERODERMA FOUNDATION.....	160
SCLERODERMA RESEARCH FOUNDATION	160
THE SCLERODERMA SOCIETY	160
SOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID)	160
SOCIETY FOR PEDIATRIC DERMATOLOGY (SPD)	160
THE STURGE-WEBER FOUNDATION	161
THE VITILIGO SOCIETY, U.K.	161
VITILIGO SUPPORT INTERNATIONAL.....	161
VZV RESEARCH FOUNDATION.....	161
XERODERMA PIGMENTOSUM SOCIETY.....	161
<i>TABLE 55 DERMATOLOGICAL ASSOCIATIONS.....</i>	<i>162</i>
<i>TABLE 55 (CONTINUED).....</i>	<i>163</i>
STRATEGIC ALLIANCES IN THE DERMATOLOGY MARKET	163
MERGERS & ACQUISITIONS	163
<i>TABLE 56 SIGNIFICANT MERGERS AND ACQUISITIONS (2005–2008)....</i>	<i>164</i>
<i>TABLE 56 (CONTINUED).....</i>	<i>165</i>
<i>TABLE 56 (CONTINUED).....</i>	<i>166</i>
VENTURE CAPITAL DEALS	166
 CHAPTER EIGHT: REGULATORY PREVIEW	 167
DRUG REGULATION IN THE UNITED STATES	167
LICENSES FOR MEDICAL DEVICES	168
DRUG REGULATION IN THE UNITED KINGDOM.....	168
LICENSES FOR DRUGS.....	169
DRUG AND EQUIPMENT APPROVAL IN EUROPE	169
LICENSES FOR MEDICAL EQUIPMENT.....	170
REIMBURSEMENT FOR DERMATOLOGICAL TREATMENT	171
REIMBURSEMENT IN THE UNITED STATES.....	171
REIMBURSEMENT IN EUROPE	172
Reimbursement in Europe (Continued).....	173
 CHAPTER NINE: MARKET METRICS.....	 174

MARKET TRENDS.....	174
BIG PHARMA’S FOCUS ON BLOCKBUSTER DRUGS ENABLES SPECIALTY FOCUS BY SMALL AND MEDIUM-SIZED FIRMS	174
COSMETIC/AESTHETIC DERMATOLOGY FACES DOWNTURN	174
CHANGES IN REIMBURSEMENT AND OTHER LEGISLATION ARE CREATING UNCERTAINTY	175
Managed Care Issues	175
Medical Liability.....	175
Physician Quality Reporting Initiative (PQRI).....	176
Dermatologic Surgery.....	176
Cosmetic Procedure Tax.....	177
INCREASED USE OF GENERICS IN PRESCRIPTION DERMATOLOGY.....	177
DIFFICULTIES IN DETERMINATION OF BIOAVAILABILITY OF TOPICAL DRUGS	178
PHYSICIAN SHORTAGE AND PARAMEDIC INFLUX IN DERMATOLOGY.....	178
CERTIFICATION EXAM FOR NURSE PRACTITIONERS IN DERMATOLOGY NOW AVAILABLE.....	179
USE OF PROCEDURE-THERAPY AND SPECIFIC DRUGS IN DERMATOLOGY.....	179
POLLUTION CONTRIBUTES TO RISE IN ATOPIC DERMATITIS	179
MANUFACTURERS OF TNF-BLOCKER DRUGS ORDERED TO HIGHLIGHT RISK OF FUNGAL INFECTIONS	180
HIGHER CO-PAYS FOR BIOLOGICS IMPACTS PRESCRIPTIONS	181
U.S. DERMATOLOGICAL MARKET.....	181
<i>TABLE 57 LEADING DRUGS PRESCRIBED BY OFFICE-BASED DERMATOLOGISTS—ALL INDICATIONS, 2008 (THOUSANDS)</i>	181
PRESCRIPTION DATA FOR ACNE.....	182
Prescription Data for Acne (Continued)	183
<i>FIGURE 3 PRESCRIBING OF ORAL ANTIBIOTICS FOR THE INTITAL TREATMENT OF ACNE: CURRENT AND IN 1 YEAR (N=75)</i>	184
<i>FIGURE 4 PRESCRIBING OF TOPICAL ANTIBIOTICS/RETINOIDS FOR ACNE: CURRENT AND IN 1 YEAR (N=75)</i>	185
<i>TABLE 58 U.S. DERMATOLOGICAL THERAPEUTICS MARKET: REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013 (\$ BILLIONS)</i>	186
<i>FIGURE 5 SHARE OF SEGMENTS IN U.S. PRESCRIPTION DERMATOLOGY MARKET, 2008 AND 2013 (%)</i>	186
<i>FIGURE 5 (CONTINUED)</i>	187
<i>FIGURE 6 LEADING PRESCRIPTION DRUG REVENUES IN GLOBAL DERMATOLOGY MARKET, 2008 (\$ MILLIONS)</i>	187
<i>FIGURE 6 (CONTINUED)</i>	188
ENBREL.....	188

<i>FIGURE 7 ENBREL SALES IN GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (% , TOTAL REVENUE = \$ 3,230 MILLION)</i>	189
<i>BOTOX</i>	190
<i>FIGURE 8 BOTOX SALES IN THE GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (% , TOTAL REVENUE = \$ 1,200 MILLION)</i>	190
<i>FIGURE 8 (CONTINUED)</i>	191
<i>LOCERYL</i>	191
<i>FIGURE 9 LOCERYL SALES IN GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (% , TOTAL = \$350 MILLION)</i>	192
<i>FIGURE 10 GLOBAL DERMATOLOGICAL PRESCRIPTION MARKET BY REGIONAL SHARE—FUTURE OUTLOOK, 2011 (%)</i>	193
<i>TABLE 59 MARKET SHARE OF PRESCRIPTION DRUG MANUFACTURERS, 2005–2007 (\$ MILLIONS)</i>	194
<i>GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET</i>	194
<i>FIGURE 11 GLOBAL DERMATOLOGICAL MARKET BY REGIONAL SHARE, 2008 (%)</i>	195
<i>TABLE 60 GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013</i>	196
<i>FIGURE 12 GLOBAL PRESCRIPTION DERMATOLOGY MARKET SHARE BY SEGMENT, 2008 (%)</i>	196
<i>FIGURE 12 (CONTINUED)</i>	197
<i>GLOBAL DERMATOLOGICAL ... (CONTINUED)</i>	198
<i>GLOBAL DERMATOLOGICAL ... (CONTINUED)</i>	199